Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Oncology ; 95(1): 8-12, 2018.
Article in English | MEDLINE | ID: mdl-29587278

ABSTRACT

OBJECTIVE: The aim of this study was to assess a risk-adapted strategy for stage I seminoma guided by the presence of rete testis invasion. METHODS: Between January 2013 and December 2015, a total of 135 consecutive patients with stage I seminoma from 18 Spanish tertiary hospitals were included in a prospective multicenter study. Median patient age was 38 years (range 22-60). Preoperative beta-human chorionic gonadotropin was elevated in 9.6% of patients. Rete testis invasion was present in 47.4% of patients. After orchiectomy, subjects with rete testis invasion were treated with 2 courses of adjuvant carboplatin (area under the curve of 7, with 21-day interval). Those without this risk factor were managed by surveillance. Disease-free survival (DFS) and overall survival (OS) were estimated with the Kaplan-Meier method. RESULTS: After a median follow-up time of 33 months, only 6 relapses were recorded (5 on surveillance, 1 after carboplatin). These cases were rescued with BEP or EP chemotherapy, and all 135 patients are currently disease free without sequelae. Three-year DFS was 92.0 and 98.2% for patients on surveillance and after carboplatin, respectively. Three-year OS was 100%. CONCLUSION: A risk-adapted approach based on rete testis invasion as a single risk factor is feasible and yielded an excellent outcome with a 3-year DFS of 94.9%.


Subject(s)
Antineoplastic Agents/therapeutic use , Carboplatin/therapeutic use , Rete Testis/pathology , Seminoma/drug therapy , Seminoma/pathology , Testicular Neoplasms/drug therapy , Testicular Neoplasms/pathology , Adult , Chorionic Gonadotropin/blood , Combined Modality Therapy , Disease-Free Survival , Humans , Male , Middle Aged , Neoplasm Staging , Orchiectomy , Prospective Studies , Seminoma/surgery , Spain , Testicular Neoplasms/surgery , Young Adult
2.
J Clin Oncol ; 26(33): 5416-21, 2008 Nov 20.
Article in English | MEDLINE | ID: mdl-18936476

ABSTRACT

PURPOSE: To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma. PATIENTS AND METHODS: Untreated patients with pure seminoma of the testis after orchiectomy, with clinical stage IIA or IIB, were considered eligible for this prospective observational study. Chemotherapy consisted of either four cycles of cisplatin and etoposide or three cycles of cisplatin, etoposide, and bleomycin. RESULTS: Between April 1994 and March 2003, 72 patients were entered onto the study at 26 participating centers. Eighteen patients had stage IIA disease, and 54 patients had stage IIB disease. Eighty-three percent of patients achieved complete response, and 17% achieved partial response with residual mass. After a median follow-up time of 71.5 months, six patients with stage IIB disease experienced relapse, and one of these patients died as a result of seminoma. Three patients experienced non-seminoma-related deaths (two died from a further esophageal carcinoma, and one died from an upper digestive hemorrhage). The estimated 5-year progression-free survival rates for patients with stage IIA or IIB disease were 100% and 87% (95% CI, 77.5% to 97%), respectively. Five-year progression-free and overall survival rates for the whole group were 90% (95% CI, 82% to 98%) and 95% (95% CI, 89% to 100%), respectively. Severe granulocytopenia and thrombocytopenia were observed in eight and two patients, respectively. Mild to moderate emesis, stomatitis, and diarrhea were the most common nonhematologic effects. CONCLUSION: Chemotherapy is a highly effective and well-tolerated treatment for patients with stage IIA or IIB seminoma and represents an available alternative that could avoid some of the serious late effects associated with radiotherapy. Further studies focusing on long-term toxicities of different treatment modalities are needed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Seminoma/drug therapy , Testicular Neoplasms/drug therapy , Adult , Aged , Bleomycin/administration & dosage , Cisplatin/administration & dosage , Combined Modality Therapy , Etoposide/administration & dosage , Humans , Male , Middle Aged , Seminoma/mortality , Seminoma/pathology , Survival Rate , Testicular Neoplasms/mortality , Testicular Neoplasms/pathology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...